Related Experiment Videos
Prevention of Rh(D) alloimmunization: a cost-benefit analysis
1Department of Obstetrics and Gynaecology, Dalhousie University, Halifax, NS.
Summary
The Rh Programme of Nova Scotia effectively prevents Rh(D) alloimmunization. Preventing this condition is significantly more cost-effective than treating it, saving healthcare resources.
Area of Science:
- Obstetrics and Gynecology
- Public Health
- Health Economics
Background:
- The Rh Programme of Nova Scotia was initiated in 1964 to combat Rh(D) alloimmunization.
- Previous studies confirmed the program's efficacy in preventing Rh(D) alloimmunization.
Purpose of the Study:
- To evaluate the cost-effectiveness of the Rh Programme of Nova Scotia amidst healthcare budget constraints.
- To compare the costs associated with preventing Rh(D) alloimmunization versus treating affected cases.
Main Methods:
- A cost-effectiveness analysis comparing prevention costs (administration, salaries, Rh immune globulin) with treatment costs for 80 Rh(D) alloimmunization cases (1982-1986).
- Detailed examination of additional healthcare services and hospital days required for treatment.
Main Results:
- Neonatal intensive care represented 80.1% of additional healthcare expenses for treated cases.
- Extended neonatal intensive care (512 extra days) constituted 65.7% of total treatment costs.
- The cost per case prevented was $1495, which is 2.7 times less than the cost per case treated ($3986).
Conclusions:
- The Rh Programme's prevention strategy is substantially more cost-effective than treating Rh(D) alloimmunization.
- Investing in Rh(D) alloimmunization prevention offers significant healthcare savings.